RIPPLE™ (implied)
Duchenne Muscular Dystrophy (DMD)
PreclinicalActive
Key Facts
About SonoThera
SonoThera is a private, preclinical-stage biotech founded in 2020, pioneering a novel non-viral gene delivery platform based on therapeutic ultrasound. The company's core technology, Ultrasound-Mediated Delivery (UMD), seeks to precisely target genetic medicines to specific organs, deliver large DNA/RNA constructs, and allow for redosing, addressing key challenges in the field. With a $125M Series B financing secured in early 2026, SonoThera is advancing a pipeline focused on genetic disorders such as Duchenne Muscular Dystrophy, Hemophilia A, and X-Linked Alport Syndrome, positioning itself as a potential disruptor in targeted genetic medicine.
View full company profileTherapeutic Areas
Other Duchenne Muscular Dystrophy (DMD) Drugs
| Drug | Company | Phase |
|---|---|---|
| DT-DEC01 | Dystrogen Therapeutics | Phase 1 |
| Skeletal Muscle Regeneration Program | IPS HEART | Pre-clinical |
| KYMBEE (deflazacort) | Upsher-Smith | Approved |
| ALY688ER | Allysta Pharmaceuticals | Phase 1 |
| AVGN7 + AVGND | AAVogen | Pre-clinical |
| Myomatrix Stabilization Program | Strykagen | Preclinical |
| Vamorolone (AGAMREE) | ReveraGen BioPharma | Approved |
| AGAMREE (vamorolone) | Catalyst Pharmaceuticals | Marketed |
| EDG-5506 | Edgewise Therapeutics | Phase 2 |
| ELEVIDYS (delandistrogene moxeparvovec-rokl) | Sarepta Therapeutics | Marketed / Phase 3 |
| SRP-5051 (vesleteplirsen) | Sarepta Therapeutics | Phase 2 |
| EXONDYS 51 (eteplirsen) | Sarepta Therapeutics | Marketed |